Requests for Application
Currently, we do not have an open Request for Application.
If you are interested in receiving e-mails regarding open calls, please send an e-mail to apply@anticancerfund.org and we will add you to the mailing list.
Closed RFA's
ATTRACT (2024)
This was an international call for research proposals on rare cancer drug development.
ATTRACT is the first international initiative to accelerate drug development for rare cancers through cross-border clinical academic research. Building on the success of the first edition (see below), we launched of a second call for projects on the 9th of September 2024.
European researchers and clinicians from different countries were invited to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancer patients.
PROTOCOL DEVELOPMENT GRANT PDAC (2024)
This grant opportunity seeked to encourage academic researchers to advance their preclinical discoveries into clinical studies.
We supportt interventions with sound preclinical data in pancreatic ductal adenocarcinoma that is mature enough to be taken forward into a clinical trial.
The aim of the grant is to aid investigators in developing and transforming their preclinical results into a high-quality clinical trial by providing seed funding to develop the protocol.
ACTION (2023)
_0.png)
This was an RFA for collaborative clinical research proposals for children with refractory high-risk neuroblastoma or relapsed neuroblastoma that:
- identify and employ novel ways to accelerate the development and delivery of clinical trials for children with neuroblastoma, and
- evaluate innovative new therapies focused on areas of unmet needs.
ATTRACT (2023)
For this RFA, 5 European anti-cancer charities joined forces to give an impulse to the field of rare cancer research.
The focus of the ATTRACT-call was on late phase (phase 2/3), collaborative, international clinical trials that aim to advance the development of better drug therapy for rare cancers.
The ATTRACT-initiative has now selected 4 projects for a total budget of 21 million euros.
Brain Metastases (2022)
This RFA aimed at increasing clinical trial activities in patients diagnosed with Brain Metastases (BM), including Leptomeningeal metastases. The focus was on innovative approaches that can improve survival rate in this patient population.
The trial selected for support for this RFA is EViDENCE, a randomised trial on a new technology that can test hundreds of drugs on small tumour samples of individual cancer patients with metastatic brain cancer.
Evolutionary Therapy (2021)
This RFA had the goal to increase clinical trial activity of evolutionarily informed therapeutic strategies to improve survival outcomes of cancer patients.
Trials that came out of this RFA are: ANZadapt and ACTOv.
ANZadapt is a Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer.
ACTOv is a multicentre phase II randomised controlled trial evaluating the efficacy of Adaptive Therapy (AT) with carboplatin in patients with ovarian cancer.
PDAC-BTC (2021)
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss-based non-profit organization, and the Anticancer Fund, once again joined forces for this RFA, that looked for proposals for clinical trials testing novel and unique strategies in the treatment of patients diagnosed with pancreatic ductal adenocarcinomas (PDAC) and/or biliary tract cancer (BTC).
The trial that was selected out of many applications is STEREOPAC, a trial combining high-dose stereotactic body radiation therapy and chemotherapy before surgery of borderline resectable pancreatic cancer.
Rare cancers (2020)
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss-based non-profit organization, and the Anticancer Fund, joined forces for this RFA in high quality clinical trials focusing on drug repurposing and therapy optimization, with special interest in rare cancers (<6/100,000), ‘Financial orphan’ drugs (commercially neglected drugs), off patent drugs and prognostic and/or predictive biomarkers.
Out of the submitted research proposals, the OligoRARE trial was selected. This trial aims at improving overall survival in patients with oligometastatic rare cancers, including all solid cancer types except lung, breast, colon, prostate cancer.
Reducing recurrence (2019)
The focus of this RFA was on cancer types with high rates of recurrence despite curative-intent treatments. This RFA was a collaboration with The Rising Tide Foundation for Clinical Cancer Research (RTFCCR).
The trial that was selected, STRASS II, is a randomised phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High-Risk Retroperitoneal Sarcoma.